9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas

Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 36

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Safety Maximum Tolerated Dose of HIOC with cisplatin and pemetrexed for Malignant Pleural Mesothelioma.,  ,  ,

Interventions: Pemetrexed, Cisplatin

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Other,

Primary Completion Date: July 2020

Completion Date: August 2020

Last  Posted Date: June 19, 2019

Location: Baylor St Lukes, Houston, Texas, United States

Website Link: https://ClinicalTrials.gov/show/NCT02838745

Was this article helpful?
Dislike 0